Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Recently, the Novo Nordisk team published an article in the Journal of Medicinal Chemistry, detailing the development of a long-acting, selective human amylin analog, NN1213 , and its preclinical study data for weight management
Two additional brief but important points
How to Choose the Right GLP-1 Medication Match the drug to your situation
(2012) demonstrated: Statistically significant reductions in visceral adipose tissue of approximately 1518% over 26 weeks compared to placebo Meaningful increases in IGF-1 levels Improvements in triglyceride profiles in some patient subgroups Effects were partially reversed upon discontinuation, suggesting that sustained benefit requires ongoing therapy The consistency of the VAT reduction finding across multiple trials is what anchors tesamorelin's clinical utility
